Navigation Links
Kyowa Hakko USA Announces GRAS Self-Affirmation for Novel Brain Health Ingredient Cognizin(R) Citicoline
Date:5/28/2009

NEW YORK, May 28 /PRNewswire/ -- Kyowa Hakko U.S.A., Inc. (Kyowa Hakko USA), the wholly owned subsidiary of Kyowa Hakko Bio Co., Ltd., (Kyowa), has announced it has completed GRAS (Generally Recognized As Safe) self-affirmation for the novel brain health ingredient Cognizin(R) Citicoline.

Cognizin(R) is a branded form of Citicoline, a natural nutrient found in every cell of the body. Citicoline provides an essential nutrient for cells -- particularly brain cells. Cognizin(R) supports brain health in several ways.

First, brain imaging technology has shown that Cognizin(R) helps increase brain energy. * Second, Cognizin(R) provides essential structural components for synthesizing brain cell membranes, which may help facilitate brain cell communication. * Lastly, Cognizin(R) helps support the formation of several brain nutrients that regulate cognitive function. * Cognizin(R) has been the subject of several human clinical trials.

The most recent trial studied the effect of Cognizin(R) on healthy middle-aged adults. Using the latest brain scanning technology, researchers at the Harvard-associated Brain Imaging Center at McLean Hospital in Boston, observed increases in brain activity among people who had taken Cognizin(R) for six weeks, particularly when individuals performed tasks that required sustained attention or memory.

Because Cognizin(R) helps make more energy available to brain cells, they are better able to perform their daily tasks. Cell membranes are synthesized and maintained. Vital brain nutrients are produced and electrical impulses are generated.

These activities may help improve the overall functioning of the brain, which is why Cognizin(R) may significantly increase the ability to focus, concentrate, and make decisions.*

Cognizin(R) Citicoline or CDP-choline will be marketed by Kyowa Hakko USA as a food ingredient in the United States for use at levels of 250 mg/serving in various food products, beverages and beverage bases, breakfast cereals, chewing gum, dairy product analogs, frozen dairy desserts, grain products and pastas, hard candies, milk and milk products, processed fruits and fruit juices, and soft candy.

In addition to Cognizin(R) brand Citicoline, Kyowa is the maker of other leading branded ingredients including Hydrafend(TM) Hyaluronic Acid, Lumistor(R) L-Hydroxyproline, Kyowa CoQ10(R), Setria(R) Glutathione and Sustamine(TM) Alanyl Glutamine. Kyowa offers manufacturers and formulators one of the industry's most extensive lines of over 50 amino acids and related compounds, including D-Amino acids and branch-chain amino acids, as well as nucleic acids, bio-products and fine chemicals.

For more information about Cognizin(R) brand Citicoline, contact Kyowa Hakko USA at 212.319.5353 or visit the web site at www.Cognizin.com.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.


'/>"/>
SOURCE Kyowa Hakko USA
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Astellas Announces New Vice President of Marketing
2. Valeant Announces Increase to Securities Repurchase Program
3. Express Scripts Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of WellPoints NextRx Subsidiaries
4. Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer
5. CenTrak Announces 16 New Deployments This Year: Company Installs Over 6 Million Square Feet in Last Six Months
6. Boston Scientific Announces Two Directors Leave Board as Burns Named CEO of Xerox and Johnson Confirmed as Under Secretary of Energy
7. WellPoint Announces Appearances at Upcoming Conferences
8. Amylin Announces Preliminary Results of Annual Meeting of Stockholders
9. Verus Pharmaceuticals Announces a Lawsuit Against AstraZeneca AB and Tika Lakemedel AB
10. Warner Chilcott Announces FDA Acceptance of NDA Submission for Low Dose Oral Contraceptive
11. gloStream Announces $7.5 Million Series B Financing Round Co-Led by Beringea and gloStreams Executive Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... August 22, 2017 , ... “Wilderness Voices”: a collection of ... “Wilderness Voices” is the creation of published author, Martha McKown, an ordained United ... inspired as a very young child when her older sisters studied High School literature. ...
(Date:8/22/2017)... ... August 22, 2017 , ... “Covert Awakening”: Walid’s ... of published author, Julianne Hale, a consultant for the Intelligence Community. For ... focusing on the Near East region. Julianne has written hundreds of reports ...
(Date:8/22/2017)... , ... August 22, 2017 , ... ... Stewart is the Founder and Managing Member for t4 Leadership Development & Consulting. ... critical to his definition of “success”: physician leadership development, servant leadership, data driven ...
(Date:8/22/2017)... ... ... “Call Of Spiritual Duty”: a revelation in an era defined by intentional ... Growing up on the streets of North Visalia, California, Carlos Lizarde quickly became familiar ... keys to his life, he noticed immediately that opportunities and blessings began to shift ...
(Date:8/21/2017)... ... August 22, 2017 , ... PracticeMatch, a company that ... healthcare employers connect with physicians and advanced practitioners like nurse practitioners and ... in August through November of this year. The online career fairs will allow ...
Breaking Medicine News(10 mins):
(Date:7/31/2017)... , July 31, 2017 Three Tru-D SmartUVC ... South Korea . Tru-D, short for "Total Room Ultraviolet ... operating rooms after an environmental services (ES) professional cleans the area with ... ... "Although the BAACH ...
(Date:7/27/2017)... 27, 2017  Zimmer Biomet Holdings, Inc. (NYSE and ... June 30, 2017.  The Company reported second quarter net ... the prior year period, and an increase of 2.1% ... points of contribution from the LDR Holding Corporation acquisition, ... quarter of 2016, or 0.3% on a constant currency ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals Company, ... our clinical trial evaluating Altemia TM , an oral ... and Sickle Cell Disease (SCD). The SCOT Trial, is ... efficacy and safety of Altemia TM in pediatric ... under US IND 125274. ...
Breaking Medicine Technology: